| heart failure | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| CIBIS, 1994 | vs placebo | cardiovascular death 0.68 [0.47; 0.98] death or HF hospitalisation 0.77 [0.61; 0.97] hospitalisation for heart failure 0.66 [0.49; 0.90] NYHA improvement 1.42 [1.02; 1.99] | | NYHA deterioration 1.18 [0.77; 1.79] all cause death 0.79 [0.57; 1.10] | | CIBIS II, 1999 | vs placebo | all cause death 0.68 [0.56; 0.82] death or HF hospitalisation 0.83 [0.75; 0.93] Sudden death 0.58 [0.41; 0.81] | | | | CIBIS II (elderly subgroup), 1999 | vs placebo | All cause death 0.70 [0.50; 0.98] | | |
| Trial | Treatments | Patients | Method |
|---|
| CIBIS, 1994 | bisoprolol 5mg/d (n=320) vs. placebo (n=321) | stable chronic idiopathic dilated cardiomyopathy heart failure NYHA 3-4, EF<40% | Double blind Parallel groups Sample size: 320/321 Primary endpoint: Mortality FU duration: 1.9 years (range 4-44 mo) | | CIBIS II, 1999 | Bisoprolol target dose 10mg/daily (n=1327) vs. control (n=1320) | chronic herat failure, ejection fraction<=35%, NYHA 3-4 | Double blind Parallel groups Sample size: 1327/1320 Primary endpoint: all-cause mortality FU duration: 1.3 years Trial stop eraly but with a planned follox-up of 24 months | | CIBIS II (elderly subgroup), 1999 | Bisoprolol (n=539) vs. placebo (n=0) | Patients aged 71 years and older | Sample size: 539/0 Primary endpoint: FU duration: |
|
